论文部分内容阅读
目的探讨脑梗死急性期血浆凝血酶原时间(PT)、活化部分凝血酶原时间(APTT)、血浆纤维蛋白(Fg)、抗血凝酶-Ⅲ(AT-Ⅲ)含量变化及临床意义,并给予药物干预。方法将95例脑梗死患者分为两组,分为进展型和完全型。分别给予抗凝和常规药物治疗,检测治疗前后上述指标变化。结果完全型脑梗死上述各凝血因子指标较正常差异无显著性,进展型Fg增高、AT-Ⅲ减少,差异有显著性。对进展型和给予低分子肝素钙注射后,可有效降低Fg、AT-Ⅲ含量。结论进展型脑梗死急性期存在血浆凝血、抗凝纤溶功能异常;给予低分子肝素钙、对治疗脑梗死急性期进展型有临床意义,提高治愈率、降低致残率。对急性期完全型脑梗死则没有临床意义。
Objective To investigate the changes and clinical significance of plasma prothrombin time (PT), partial prothrombin time (APTT), plasma fibrin (Fg) and antithrombin-Ⅲ (AT-Ⅲ) Give medical intervention. Methods 95 patients with cerebral infarction were divided into two groups, divided into progressive and complete type. Respectively given anticoagulant and conventional drug treatment, testing before and after treatment of these indicators change. Results The indexes of all the above clotting factors in the patients with complete cerebral infarction had no significant difference compared with the normal ones. The progressively increased Fg and the AT-Ⅲ decreased, the difference was significant. The progress of type and given low molecular weight heparin after injection, can effectively reduce the Fg, AT-Ⅲ content. Conclusions There is abnormal plasma coagulation and anticoagulant fibrinolytic activity in the acute stage of progressing cerebral infarction. Given low molecular weight heparin, it is of clinical significance to improve the acute stage of cerebral infarction and improve the cure rate and reduce the morbidity. The acute phase of complete cerebral infarction is of no clinical significance.